ArticleJournal of Alzheimer's disease reports
TREM2 in Alzheimer's disease: A global bibliometric analysis of research evolution and therapeutic implications.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor genetically linked to Alzheimer's disease (AD) and increasingly recognized as a key regulator of neuroinflammation, yet its global research landscape in AD remains unclear. Objective: In the central nervous system, TREM2 expressed on microglia is closely related to the occurrence and development of AD and has been extensively studied in recent years. However, there is still a lack of bibliometric analysis regarding TREM2 and AD. Methods: We searched in the Web of Science Core Collection (WoSCC) for articles published from January 1, 2000, to September 30, 2024. After a thorough screening process, we selected relevant information regarding TREM2 and AD. Subsequently, a comprehensive analysis was conducted on a total of 944 publications. The analysis utilized GraphPad Prism 9, CiteSpace6.1.6, VOSviewer1.6.19, the Online Analysis Platform of Literature Metrology, GeneMANIA and Metascape. Results: A total of 944 publications from 2000 to 2024 met the inclusion criteria for this analysis. Over this period, research activity in TREM2 and AD has shown a consistent upward trend, with notable peaks in 2021 and 2022. The United States and China lead in the number of publications, with Washington University being the top research institution. Conclusions: This study employs advanced bibliometric analysis tools and visualization techniques to clearly present the major research themes, development trends, and prospects of TREM2 in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.